1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Adeno Carcinomas
1.2.3 Mucinous Carcinomas
1.2.4 Adenosquamous Carcinomas
1.3 Market by Application
1.3.1 Global mRNA Cancer Vaccines and Therapeutics Market Share by Application: 2020 VS 2026
1.3.2 Infectious Disease
1.3.3 Cancer
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global mRNA Cancer Vaccines and Therapeutics Market Perspective (2015-2026)
2.2 Global mRNA Cancer Vaccines and Therapeutics Growth Trends by Regions
2.2.1 mRNA Cancer Vaccines and Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 mRNA Cancer Vaccines and Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 mRNA Cancer Vaccines and Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top mRNA Cancer Vaccines and Therapeutics Players by Market Size
3.1.1 Global Top mRNA Cancer Vaccines and Therapeutics Players by Revenue (2015-2020)
3.1.2 Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Players (2015-2020)
3.2 Global mRNA Cancer Vaccines and Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by mRNA Cancer Vaccines and Therapeutics Revenue
3.4 Global mRNA Cancer Vaccines and Therapeutics Market Concentration Ratio
3.4.1 Global mRNA Cancer Vaccines and Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by mRNA Cancer Vaccines and Therapeutics Revenue in 2019
3.5 Key Players mRNA Cancer Vaccines and Therapeutics Area Served
3.6 Key Players mRNA Cancer Vaccines and Therapeutics Product Solution and Service
3.7 Date of Enter into mRNA Cancer Vaccines and Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 mRNA Cancer Vaccines and Therapeutics Breakdown Data by Type (2015-2026)
4.1 Global mRNA Cancer Vaccines and Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global mRNA Cancer Vaccines and Therapeutics Forecasted Market Size by Type (2021-2026)
5 mRNA Cancer Vaccines and Therapeutics Breakdown Data by Application (2015-2026)
5.1 Global mRNA Cancer Vaccines and Therapeutics Historic Market Size by Application (2015-2020)
5.2 Global mRNA Cancer Vaccines and Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America mRNA Cancer Vaccines and Therapeutics Market Size (2015-2026)
6.2 North America mRNA Cancer Vaccines and Therapeutics Market Size by Type (2015-2020)
6.3 North America mRNA Cancer Vaccines and Therapeutics Market Size by Application (2015-2020)
6.4 North America mRNA Cancer Vaccines and Therapeutics Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe mRNA Cancer Vaccines and Therapeutics Market Size (2015-2026)
7.2 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Type (2015-2020)
7.3 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Application (2015-2020)
7.4 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe
(2015-2020)
(2015-2020)
.4 mRNA Cancer Vaccines and Therapeutics Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific
(2015-2020)
(2015-2020)
.4 mRNA Cancer Vaccines and Therapeutics Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil
.4 mRNA Cancer Vaccines and Therapeutics Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa
8Key Players Profiles
8.1 Moderna Therapeutics
8.1.1 Moderna Therapeutics Company Details
8.1.2 Moderna Therapeutics Business Overview
8.1.3 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Introduction
8.1.4 Moderna Therapeutics Revenue in mRNA Cancer Vaccines and Therapeutics Business (2015-2020))
8.1.5 Moderna Therapeutics Recent Development
8.2 CureVac
8.2.1 CureVac Company Details
8.2.2 CureVac Business Overview
8.2.3 CureVac mRNA Cancer Vaccines and Therapeutics Introduction
8.2.4 CureVac Revenue in mRNA Cancer Vaccines and Therapeutics Business (2015-2020)
8.2.5 CureVac Recent Development
8.3 Translate Bio
8.3.1 Translate Bio Company Details
8.3.2 Translate Bio Business Overview
8.3.3 Translate Bio mRNA Cancer Vaccines and Therapeutics Introduction
8.3.4 Translate Bio Revenue in mRNA Cancer Vaccines and Therapeutics Business (2015-2020)
8.3.5 Translate Bio Recent Development
8.4 BioNTech
8.4.1 BioNTech Company Details
8.4.2 BioNTech Business Overview
8.4.3 BioNTech mRNA Cancer Vaccines and Therapeutics Introduction
8.4.4 BioNTech Revenue in mRNA Cancer Vaccines and Therapeutics Business (2015-2020)
8.4.5 BioNTech Recent Development
8.5 Sangamo Therapeutics
8.5.1 Sangamo Therapeutics Company Details
8.5.2 Sangamo Therapeutics Business Overview
8.5.3 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Introduction
8.5.4 Sangamo Therapeutics Revenue in mRNA Cancer Vaccines and Therapeutics Business (2015-2020)
8.5.5 Sangamo Therapeutics Recent Development
8.6 Argos Therapeutics
8.6.1 Argos Therapeutics Company Details
8.6.2 Argos Therapeutics Business Overview
8.6.3 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Introduction
8.6.4 Argos Therapeutics Revenue in mRNA Cancer Vaccines and Therapeutics Business (2015-2020)
8.6.5 Argos Therapeutics Recent Development
8.7 In-Cell-Art
8.7.1 In-Cell-Art Company Details
8.7.2 In-Cell-Art Business Overview
8.7.3 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Introduction
8.7.4 In-Cell-Art Revenue in mRNA Cancer Vaccines and Therapeutics Business (2015-2020)
8.7.5 In-Cell-Art Recent Development
8.8 eTheRNA
8.8.1 eTheRNA Company Details
8.8.2 eTheRNA Business Overview
8.8.3 eTheRNA mRNA Cancer Vaccines and Therapeutics Introduction
8.8.4 eTheRNA Revenue in mRNA Cancer Vaccines and Therapeutics Business (2015-2020)
8.8.5 eTheRNA Recent Development
8.9 Ethris
8.9.1 Ethris Company Details
8.9.2 Ethris Business Overview
8.9.3 Ethris mRNA Cancer Vaccines and Therapeutics Introduction
8.9.4 Ethris Revenue in mRNA Cancer Vaccines and Therapeutics Business (2015-2020)
8.9.5 Ethris Recent Development
8.10 Tiba Biotechnology
8.10.1 Tiba Biotechnology Company Details
8.10.2 Tiba Biotechnology Business Overview
8.10.3 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Introduction
8.10.4 Tiba Biotechnology Revenue in mRNA Cancer Vaccines and Therapeutics Business (2015-2020)
8.10.5 Tiba Biotechnology Recent Development
9Analyst’s Viewpoints/Conclusions
10Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Disclaimer
10.3 Author Details
【掲載企業】
Moderna Therapeutics、CureVac、Translate Bio、BioNTech、Sangamo Therapeutics、Argos Therapeutics、In-Cell-Art、eTheRNA、Ethris、Tiba Biotechnology
【免責事項】
https://www.globalresearch.jp/disclaimer